Aarmed Formulations Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 9.72 M
as on 16-11-2024
- Company Age 25 Year, 7 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 11.14 Cr
as on 16-11-2024
- Revenue -56.71%
(FY 2023)
- Profit -77.09%
(FY 2023)
- Ebitda -69.23%
(FY 2023)
- Net Worth 22.95%
(FY 2023)
- Total Assets -11.34%
(FY 2023)
About Aarmed Formulations
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 9.72 M.
The company currently has active open charges totaling ₹11.14 Cr.
Jyoti Agrawal and Pooja Agrawal serve as directors at the Company.
- CIN/LLPIN
U24231UP2000PTC025014
- Company No.
025014
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Jan 2000
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Gorakhpur, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Aarmed Formulations Private Limited offer?
Aarmed Formulations Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Pre & Probiotic Capsule.
Who are the key members and board of directors at Aarmed Formulations?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jyoti Agrawal  | Director | 03-Jan-2000 | Current |
| Pooja Agrawal | Director | 08-Feb-2021 | Current |
Financial Performance of Aarmed Formulations.
Aarmed Formulations Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 56.71% decrease. The company also saw a substantial fall in profitability, with a 77.09% decrease in profit. The company's net worth Soared by an impressive increase of 22.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aarmed Formulations?
In 2023, Aarmed Formulations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 22 Nov 2019 | ₹10.48 Cr | Open |
Others Creation Date: 03 Oct 2016 | ₹6.60 M | Open |
How Many Employees Work at Aarmed Formulations?
Aarmed Formulations has a workforce of 14 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aarmed Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aarmed Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
